Birchview Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Birchview Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,300	Closed	-$344K	–	51
2020 Q3	$344K	Hold	8,300	–	–	0.23%	40
2020 Q2	$398K	Hold	8,300	–	–	0.24%	39
2020 Q1	$523K	Hold	8,300	–	–	0.46%	28
2019 Q4	$1.03M	Hold	8,300	–	–	0.75%	21
2019 Q3	$551K	Hold	8,300	–	–	0.37%	26
2019 Q2	$660K	Hold	8,300	–	–	0.4%	28
2019 Q1	$928K	Buy	8,300 +4,000	+93%	+$437K	0.58%	18
2018 Q4	$433K	Hold	4,300	–	–	0.41%	29
2018 Q3	$543K	Hold	4,300	–	–	0.35%	31
2018 Q2	$361K	Hold	4,300	–	–	0.25%	39
2018 Q1	$265K	Hold	4,300	–	–	0.17%	40
2017 Q4	$251K	Hold	4,300	–	–	0.15%	34
2017 Q3	$250K	Buy	+4,300	New	+$463K	0.13%	32
2016 Q4	–	Sell	-1,300	Closed	-$214K	–	43
2016 Q3	$214K	Hold	1,300	–	–	0.12%	36
2016 Q2	$185K	Hold	1,300	–	–	0.13%	35
2016 Q1	$167K	Buy	+1,300	New	+$153K	0.12%	37

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Birchview Capital's ICPT Position: Q4 2020 in Review

Birchview Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 8,300 shares — an estimated $344K sold.

Birchview Capital first reported a position in ICPT in Q1 2016 and held it in 16 quarters. The position peaked at $1.03M in Q4 2019. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

Birchview Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Birchview Capital sold 8,300 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $344K.
Birchview Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2016 and held it in 16 quarters.
Birchview Capital's Intercept Pharmaceuticals, Inc. position peaked at $1.03M in Q4 2019.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Birchview Capital's 13F filing for Q4 2020, filed 9 Feb 2021.